Literature DB >> 19826970

The pathology of drug-induced liver injury.

David E Kleiner1.   

Abstract

The liver biopsy is frequently used as an adjunct diagnostic test in the evaluation of drug-induced liver injury (DILI). A biopsy may be performed to confirm the diagnosis, especially when there is a complex clinical differential diagnosis that includes DILI. A biopsy can also be used to stage the severity of hepatotoxicity so that a necessary agent may be continued. Alternatively, a drug or toxin may only be implicated after a biopsy is performed, particularly in the case of subacute or chronic liver injury. The pathologist should approach the biopsy systematically by first classifying the disease and then working with the clinician to include or exclude etiologies in the pathological differential diagnosis. This article outlines a practical approach to the diagnosis of DILI on liver biopsy, including the common patterns of injury observed in drug- and toxin-induced liver pathology and prognostic pathological features that may be associated with the outcome of patients with DILI.

Entities:  

Mesh:

Year:  2009        PMID: 19826970     DOI: 10.1055/s-0029-1240005

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  29 in total

1.  Jaundice due to suspected statin hepatotoxicity: a case series.

Authors:  Ottar M Bergmann; Gudjon Kristjansson; Jon G Jonasson; Einar S Björnsson
Journal:  Dig Dis Sci       Date:  2011-11-11       Impact factor: 3.199

2.  The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury.

Authors:  Ayako Suzuki; Elizabeth M Brunt; David E Kleiner; Rosa Miquel; Thomas C Smyrk; Raul J Andrade; M Isabel Lucena; Agustin Castiella; Keith Lindor; Einar Björnsson
Journal:  Hepatology       Date:  2011-08-08       Impact factor: 17.425

3.  Diagnosis: Liver biopsy differentiates DILI from autoimmune hepatitis.

Authors:  James H Lewis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-23       Impact factor: 46.802

4.  The Role of the Hepatopathologist in the Assessment of Drug-induced Liver Injury.

Authors:  David E Kleiner
Journal:  Clin Liver Dis (Hoboken)       Date:  2017-03-01

5.  Automated Machine Learning Diagnostic Support System as a Computational Biomarker for Detecting Drug-Induced Liver Injury Patterns in Whole Slide Liver Pathology Images.

Authors:  Munish Puri
Journal:  Assay Drug Dev Technol       Date:  2019-05-31       Impact factor: 1.738

6.  Development of fatal acute liver failure in HIV-HBV coinfected patients.

Authors:  Albert M Anderson; Marina B Mosunjac; Melody P Palmore; Melissa K Osborn; Andrew J Muir
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

Review 7.  Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.

Authors:  Rashmi R Shah; Joel Morganroth; Devron R Shah
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.606

8.  Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.

Authors:  Robert J Fontana; Leonard B Seeff; Raúl J Andrade; Einar Björnsson; Christopher P Day; Jose Serrano; Jay H Hoofnagle
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

9.  Pathology of flupirtine-induced liver injury: a histological and clinical study of six cases.

Authors:  Florian Puls; Clemens Agne; Fritz Klein; Martin Koch; Kinan Rifai; Michael P Manns; Jürgen Borlak; Hans H Kreipe
Journal:  Virchows Arch       Date:  2011-05-18       Impact factor: 4.064

10.  Amoxicillin-Clavulanate-Induced Liver Injury.

Authors:  Andrew S deLemos; Marwan Ghabril; Don C Rockey; Jiezhun Gu; Huiman X Barnhart; Robert J Fontana; David E Kleiner; Herbert L Bonkovsky
Journal:  Dig Dis Sci       Date:  2016-03-22       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.